Peptide receptor radionuclide therapy during the COVID-19 pandemic: Are there any concerns?

Lisa Bodei; Emily Bergsland; Wouter W. de Herder; Diego Ferone; Rodney J. Hicks; Thomas A. Hope; Jolanta Kunikowska; Marianne Pavel; Diane Reidy-Lagunes; Jens Siveke; Jonathan Strosberg; Ulf Dittmer; Ken Herrmann

doi:10.2967/jnumed.120.249136

Peptide receptor radionuclide therapy during the COVID-19 pandemic: Are there any concerns?

Lisa Bodei, Emily Bergsland, Wouter W. de Herder, Diego Ferone, Rodney J. Hicks, Thomas A. Hope, Jolanta Kunikowska, Marianne Pavel, Diane Reidy-Lagunes, Jens Siveke, Jonathan Strosberg, Ulf Dittmer, Ken Herrmann

Research output: Contribution to journal › Editorial

7 Scopus citations

Original language	English
Pages (from-to)	1094-1095
Number of pages	2
Journal	Journal of Nuclear Medicine
Volume	61
Issue number	8
DOIs	https://doi.org/10.2967/jnumed.120.249136
State	Published - 1 Aug 2020
Externally published	Yes

Access to Document

10.2967/jnumed.120.249136

Cite this

Bodei, L., Bergsland, E., de Herder, W. W., Ferone, D., Hicks, R. J., Hope, T. A., Kunikowska, J., Pavel, M., Reidy-Lagunes, D., Siveke, J., Strosberg, J., Dittmer, U., & Herrmann, K. (2020). Peptide receptor radionuclide therapy during the COVID-19 pandemic: Are there any concerns? Journal of Nuclear Medicine, 61(8), 1094-1095. https://doi.org/10.2967/jnumed.120.249136

@article{c379feaee3b54289a6cd90c82635ea75,

title = "Peptide receptor radionuclide therapy during the COVID-19 pandemic: Are there any concerns?",

author = "Lisa Bodei and Emily Bergsland and \{de Herder\}, \{Wouter W.\} and Diego Ferone and Hicks, \{Rodney J.\} and Hope, \{Thomas A.\} and Jolanta Kunikowska and Marianne Pavel and Diane Reidy-Lagunes and Jens Siveke and Jonathan Strosberg and Ulf Dittmer and Ken Herrmann",

note = "Funding Information: Lisa Bodei has an unpaid position on a consultancy or advisory board for AAA, Ipsen, Curium, and Clovis Oncology and performs research for AAA. Emily Bergsland has an unpaid position on an advisory board for AAA. Wouter de Herder is on an advisory board for AAA-Novartis and Wren labs; receives speaker fees from Ipsen, Pfizer, AAA-Novartis, and Novartis; and is on a steering committee for NETTER 2. Diego Ferone is on a steering committee for NETTER 2. Rodney Hicks holds stocks in and is a scientific advisor to Telix Pharmaceuticals (all proceeds donated to his institution). Thomas Hope is on a consultancy or advisory board for Curium and Ipsen; performs research for Clovis Oncology and Philips; and is a trial participant for Novartis and AAA. Marianne Pavel receives honoraria for presentations and a consultancy from Novartis, IPSEN, AAA, Pfizer, and Lexicon. Diane Reidy-Lagunes is on an advisory board for AAA and Lexicon and performs research for Novartis, Ipsen, and Merck. Jens Siveke receives research funding from Celgene and BMS; is on a consulting or advisory board for Celgene, AstraZeneca, and Roche; receives travel funds from Roche, Celgene, BMS, AstraZeneca, and Servier; and holds ownership in FAPI Holding (,3\%). Jonathan Strosberg is on a speaker{\textquoteright}s bureau for Lexicon and Ipsen and is a consultant for Novartis. Ken Herrmann is a consultant for Bayer, Sofie Biosciences, SIRTEX, AAA, Curium, Endocyte, BTG, Ipsen, Siemens Healthcare, GE Healthcare, Amgen, Novartis, and Ymabs and holds stock options (,1\%) in Sofie Biosciences. No other potential conflict of interest relevant to this article was reported.",

year = "2020",

month = aug,

day = "1",

doi = "10.2967/jnumed.120.249136",

language = "English",

volume = "61",

pages = "1094--1095",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "8",

}

TY - JOUR

T1 - Peptide receptor radionuclide therapy during the COVID-19 pandemic

T2 - Are there any concerns?

AU - Bodei, Lisa

AU - Bergsland, Emily

AU - de Herder, Wouter W.

AU - Ferone, Diego

AU - Hicks, Rodney J.

AU - Hope, Thomas A.

AU - Kunikowska, Jolanta

AU - Pavel, Marianne

AU - Reidy-Lagunes, Diane

AU - Siveke, Jens

AU - Strosberg, Jonathan

AU - Dittmer, Ulf

AU - Herrmann, Ken

N1 - Funding Information: Lisa Bodei has an unpaid position on a consultancy or advisory board for AAA, Ipsen, Curium, and Clovis Oncology and performs research for AAA. Emily Bergsland has an unpaid position on an advisory board for AAA. Wouter de Herder is on an advisory board for AAA-Novartis and Wren labs; receives speaker fees from Ipsen, Pfizer, AAA-Novartis, and Novartis; and is on a steering committee for NETTER 2. Diego Ferone is on a steering committee for NETTER 2. Rodney Hicks holds stocks in and is a scientific advisor to Telix Pharmaceuticals (all proceeds donated to his institution). Thomas Hope is on a consultancy or advisory board for Curium and Ipsen; performs research for Clovis Oncology and Philips; and is a trial participant for Novartis and AAA. Marianne Pavel receives honoraria for presentations and a consultancy from Novartis, IPSEN, AAA, Pfizer, and Lexicon. Diane Reidy-Lagunes is on an advisory board for AAA and Lexicon and performs research for Novartis, Ipsen, and Merck. Jens Siveke receives research funding from Celgene and BMS; is on a consulting or advisory board for Celgene, AstraZeneca, and Roche; receives travel funds from Roche, Celgene, BMS, AstraZeneca, and Servier; and holds ownership in FAPI Holding (,3%). Jonathan Strosberg is on a speaker’s bureau for Lexicon and Ipsen and is a consultant for Novartis. Ken Herrmann is a consultant for Bayer, Sofie Biosciences, SIRTEX, AAA, Curium, Endocyte, BTG, Ipsen, Siemens Healthcare, GE Healthcare, Amgen, Novartis, and Ymabs and holds stock options (,1%) in Sofie Biosciences. No other potential conflict of interest relevant to this article was reported.

PY - 2020/8/1

Y1 - 2020/8/1

UR - http://www.scopus.com/inward/record.url?scp=85089126063&partnerID=8YFLogxK

U2 - 10.2967/jnumed.120.249136

DO - 10.2967/jnumed.120.249136

M3 - Editorial

C2 - 32576637

AN - SCOPUS:85089126063

SN - 0161-5505

VL - 61

SP - 1094

EP - 1095

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 8

ER -

Peptide receptor radionuclide therapy during the COVID-19 pandemic: Are there any concerns?

Access to Document

Other files and links

Cite this